Abstract Mucoepidermoid carcinoma (MEC) is a relatively common salivary tumor with varying potential for aggressive behavior. Mucoepidermoid carcinoma grading has evolved from descriptive two-tiered schemata to more objective three-tiered systems. In 2001, we published a grading system Brandwein et al. in Am J Surg Pathol 25:835-845, (2001) which modified the prevailing criteria of Auclair et al. in Cancer 69:2021-2030 (1992 , and included additional features of aggressive MEC. Here we seek to validate our modified grading system in a new multicenter cohort. The retrospective cohort consisted of 76 patients with confirmed MEC and known outcome data. The resection specimens were reviewed and uniformly graded according to our modified criteria Brandwein et al. in Am J Surg Pathol 25: 835-845 (2001), and the Auclair criteria Auclair et al. in Cancer 69:2021-2030 , (1992 , Goode et al. in Cancer 82:1217-1224 , (1998 . Case distribution was as follows: Montefiore Medical Center: 41 (1977-2009, University of Alabama at Birmingham: 21 (1999-2010), and Rhode Island Hospital: 14, (1995-2011. Patient age ranged from 7 to 81 years (mean 51 years). The female to male ratio was 3:1. The most commonly involved sites were: parotid: n = 39 (51 %), palate: n = 10 (13 %), retromolar trigone: n = 6 (8 %), buccal: n = 5 (7 %), and submandibular gland: n = 5 (7 %). The modified criteria upgraded 41 % MEC; 20/25 MEC from AFIP
Introduction
Mucoepidermoid carcinoma (MEC) is a common salivary tumor with varying potential for aggressive behavior. The diagnosis of MEC is based on the identification of three intermixed tumor elements: mucin-producing cells, intermediate and/or clear cells, and squamoid cells. The grading of MEC has evolved over time from descriptive two-tiered schemata to more objective three-tiered systems. Mucoepidermoid carcinoma classified as low-grade, (Grade 1) usually do not metastasize and are often cured by appropriate surgery. Patients with MEC classified as high-grade, (Grade 3) are at significant risk for presenting with positive lymph nodes and developing disease-progression, and possibly disease-related mortality. The expectation is that the biologic potential of intermediate-grade (Grade 2) MEC lies somewhere in the spectrum between Grades 1 and 3 tumors. However the question as to how to treat a particular individual with Grade 2 MEC can be vexing, especially for surgeons prone to dichotomization. In response to the observation that some patients with MEC classified as Grade 1 by the prevailing criteria of Auclair and colleagues (also referred to as the Armed Forced Institute of Pathology (AFIP) criteria) developed metastases or disease-related mortality, [2, 3] we published a modified grading system in 2001 [1] . Here we present the histological detail which will allow others to use this modified grading system. We also attempt to validate our modified grading system in a new multicenter patient cohort.
Materials and Methods
The pathology files from Montefiore Medical Center (MMC), University of Alabama at Birmingham (UAB), and Rhode Island Hospital (RIH), were searched for all diagnoses of ''mucoepidermoid carcinoma'' involving head and neck sites; the search extended as far back as feasible for each institution. This study was approved by the Institutional Review Boards at MMC, UAB and RIH. We limited our review to the resection specimens from patients treated by primary surgery. All of the pathology slides were re-reviewed, and only tumors with adequate pathological documentation which fulfilled the diagnostic criteria for mucoepidermoid carcinoma (MEC) were included for study; those criteria are: ''a malignant glandular epithelial neoplasm characterized by mucous, intermediate and epidermoid cells, with columnar, clear cell and oncocytoid features [4] .'' Data were collected regarding patient age, gender, tumor site, stage, margin status, date of primary surgery, adjuvant treatment, date of first disease progression event (either locoregional recurrence or distant metastases) versus last known date without evidence of disease, and date of death (overall survival) versus last known date alive. The retrospective nature of this study did not allow for assessment of disease-specific mortality. The MEC were graded according to the published AFIP [1, 2] and the Brandwein modified grading criteria [3] (Table 1) blinded to outcome. Specific information regarding the grading of MEC will be presented in the Sect. ''Discussion''. Margin status was assessed histologically as the closest margin in millimeters. Disease progression was classified as either locoregional recurrence or distant metastases. Care was taken to distinguish disease persistence after initial surgical intervention from true local recurrence; this will be further discussed in the Sect. ''Results''. For patients with persistent disease, the date of definitive surgery with curative intent was used as the date of initial treatment.
Associations between tumor grade, tumor site (major versus minor), stage, and disease progression were assessed by Fisher exact test or Chi squared test; all tests were 2-tailed, with a probability value of less than 0.05 considered statistically significant. Univariate Kaplan-Meier analysis was performed to assess time to disease progression stratified for patient gender, tumor site (major versus minor), margin status, stage, and MEC grade, according to the AFIP criteria and the modified grading schema, using the MedCalc program. It is quite probable that some patients classified as ''surgery only'' may have received adjuvant radiation at other facilities. Therefore treatment status could not be considered in the outcome analyses and multivariate analysis was not feasible.
Results
One hundred and thirteen resections with adequate diagnostic material were reviewed; 34 tumors were reclassified as either ''suspicious for metastatic squamous cell carcinoma'' (n = 16), ''high-grade salivary duct carcinoma'' (n = 4), ''carcinoma-ex-pleomorphic adenoma'' (n = 4), ''adenocarcinoma not otherwise specified'' (n = 3), ''pleomorphic adenoma with MEC metaplasia'' (n = 3), ''cystadenoma'' (n = 1), ''sebaceous carcinoma'' (n = 1), ''low-grade salivary duct carcinoma'' (n = 1), and ''sclerosing polycystic adenosis'' (n = 1), and excluded from study. (1995) (1996) (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) . The patient age range at diagnosis was 7-81 years (mean 51 years). There was a female to male ratio of 3:1. The distribution of involved anatomic sites was as follows: parotid: n = 39 (51 %), palate: n = 10 (13 %), retromolar trigone: n = 6 (8 %), buccal: n = 5 (7 %), submandibular gland: n = 5 (7 %), tongue: n = 3 (4 %), sinonasal tract: n = 2 (3 %), sublingual gland: n = 2 (3 %), lower lip: n = 1 (1 %), mandible: n = 1 (1 %), maxilla: n = 1 (1 %), and oral cavity not otherwise specified: n = 1 (1 %). Tumor stage at presentation was known for 64 patients; 61 % (39/64) presented with Stage I/II disease and 39 % (25/64) presented with Stage III/IV disease. No association between tumor stage and tumor site (major versus minor salivary grand sites) was seen (Fisher 2-tailed exact test). Margin status could be histologically determined for 71 patients: six patients had margins C2 mm, 44 patients had margins of 1 mm, and 21 patients had margins B1 mm.
The Modified MEC Grading Schema includes three additional grading variables: (1) aggressive pattern of invasion, (2) bony invasion, and (3) Eleven patients had positive lymph nodes ( Table 2 ). The AFIP grade distribution for these MEC was Grade 1: 3/11, Grade 2: 1/11, and Grade 3: 7/11; the grade distribution by the modified grading criteria was Grade 1: 0/11, Grade 2: 1/11, and Grade 3: 10/11. Grade 1 by the modified grading criteria was significantly predictive of negative cervical lymph nodes (p = 0.0001, Chi-square test, 2DF).
Eight patients had local disease persistence after initial intervention. One patient was deliberately not treated with curative intent due to a competing illness (colon adenocarcinoma); he was omitted from further survival analyses. The seven other patients had persistent disease for a number of reasons; their date of definitive surgery with curative intent was used as the date of initial treatment. One patient presented with a parotid MEC in 2006 which represented metastasis from a sinonasal primary MEC discovered in 2007; she remains disease-free after resection and adjuvant radiation therapy as of 2010. Inadequate initial resection accounted for the remaining six patients with local disease persistence. One patient had a cyst excised from cervical level I in 1997, which was diagnosed as a ''benign cyst'' level ( Fig. 1) . This represented an unrecognized Grade I MEC with a prominent cystic component. Definitive resection of her parotid MEC was performed in 2006, and she remained disease-free in 2009. Five other patients with incomplete resections presented with local persistence at the identical site within 1 year. Initial local tumor persistence was significantly associated with MEC grade (by both criteria, p \ 0.0001, Chi square 2DF). No significant association was found between initial tumor persistence and stage or site (minor vs. major).
One patient developed a second contralateral MEC which was not considered as disease progression; she remained progression-free from both MEC. Nine patients 
developed disease progression after a mean of 18 months: four patients developed metastatic disease (involving either lungs, or numerous sites including multiple lymph nodes and cutaneous metastases) and five patients developed locoregional recurrence after definite treatment ( For the nine patients with disease progression, the modified grading schema classified eight MEC as Grade 3 and one MEC as Grade 2. By comparison, the AFIP grading schema classified three of these MEC as Grade 1, and the remaining 6 as Grade 3. The predictive performance of the two grading schema could not be compared due to the small number of patients who experienced disease progression and were reclassified with respect to grade (n = 3).
Discussion
The MEC monograph published by Stewart in 1945 described and illustrated two phenotypes for MEC, one ''relatively favorable'' versus the other ''highly unfavorable'' [5] . The two-tiered theme is reiterated in the monograph published in 1953 by Foote and Frazell, who described low-and high-grade tumors, but also offered a rationale for the ''medium-grade'' category which ''bears more resemblance to the quite low-grade than to the highly aggressive types [6] .'' Neither manuscript offered the reader exact guidelines as to how to distinguish between the different grades. Jakobsson and colleagues reported the outcome of 63 patients with MEC who were likewise divided into two groups [7] . Their formula for separating low-and high-grade MEC was succinct, ''Infiltrative growth was used as the sole criterion qualifying a tumor as high-grade malignancy''. Evans was equally succinct, relying solely on a cut-off of 90 % solid, non-cystic architecture to categorize MEC as high-grade [8] . The inherent appeal of a simple two-tiered grading schema is that one can expect greater uniformity in its application between pathologists. It also offers surgeons simpler choices in terms of formulating treatment plans.
The classification of MEC as low-grade usually signifies potentially curable disease. All MEC require complete resection with negative margins; inadequate resection margins should be addressed by re-excision if feasible. The classification of MEC as high-grade connotes the potential for disease-progression and the possibly of disease-related mortality. In addition to complete resection, post-operative adjuvant radiotherapy is indicated for high-grade MEC. The introduction of three-tiered grading systems was [9] , and Batsakis and Luna in 1990 [10] . The point-based three-tiered grading system published by Ellis, Auclair, and Goode [2, 3] represented a major point of departure in that it was the first proposed grading schema with the potential of enhancing reproducibility between pathologists. Patient outcome was classified into four groups: ''Group 1 patients experienced survival without disease, Group 2 patients demonstrated survival with tumor recurrence only, Group 3 patients survived with metastasis, and Group 4 patients died of disease.'' However, a number of patients classified as having ''low-grade'' MEC by these criteria had more aggressive disease than would be expected for truly lowgrade tumors. Their outcome Group 3 contained 10 patients with Grade 1 MEC: seven with major and three with minor salivary gland tumors, respectively [2, 3] . Ten patients with Grade 1 major salivary MEC were classified as developing ''death related to tumor'' (outcome group 4) [3] . These outcomes were the impetus for modifying the grading criteria to improve predictive performance. One could argue that presentation with lymph node metastases, and certainly development of disease-related mortality, mitigate against the classification of ''low-grade''.
The above paradox for AFIP Grade 1 MEC patients served as the rationale for the ''Modified MEC Grading Schema'', which includes three additional grading variables: (1) aggressive pattern of invasion, (2) lymphovascular invasion, and (3) bony invasion. Furthermore, there is greater weight assigned to perineural invasion (?3 points), and the cut-off scores per category were shifted. These three histological features now merit further description. Mucoepidermoid carcinoma with ''nonaggressive pattern of invasion'' are defined as circumscribed tumors, which do not directly invade into adjacent parenchyma. A fibrous capsule might be present. If separate ''breakaway'' tumor satellites are seen, they remained confined to the circumscribed tumor profile (Fig. 2) .
Mucoepidermoid carcinoma with ''aggressive pattern of invasion'' are characterized by irregular tumor contours demonstrating separate ''break-away'' islands and direct invasion into adjacent parenchyma (Figs. 3, 4) . This description harkens back to Jakobsson's dichotomized criteria [7] . These ''break-away'' MEC islands may be either solid or cystic, and variably sized. Importantly, MEC with extravasated mucin should also be classified as aggressive pattern of invasion; this finding was very common to patients who experienced local tumor persistence due to inadequate resection. Tumor cells are commonly found within the extravasated mucin, which should be considered as having the potential for local recurrence/persistence, even if no tumor cells are seen. There was no evidence to suggest that local tumor persistence negatively impacts overall survival. However, patients may require larger, more disfiguring surgeries to address tumor persistence. Lymphovascular invasion (LVI) is a logical inclusion in the modified grading schema. Twelve MEC (16 %) were classified as having LVI, resulting in the upgrading of three tumors from AFIP Grade 1 MEC (2) and Grade 2 MEC (1) to Grade 3. One of these 12 patients did not receive definite treatment due to competing illness (colonic adenocarcinoma). Five of the remaining 10 MEC patients with LVI developed disease progression. The rationale for adding bony invasion to the modified grading criteria might not be as obvious. One could argue that bony invasion is accounted for in the TNM staging, and therefore should not be considered twice. However, multivariate regression analysis was not feasible either in our original manuscript [1] or the present study; thus bony invason ''was not considered twice''. Bony invasion was present in three MEC (4 %) resulting in the upgrading of two tumors from AFIP Grade 1 MEC (1) and Grade 2 MEC (1) to Grade 3. One of these three patients did not receive definitive treatment as described above. One of the remaining two patients with bone invason went on to develop disease progression.
Nuclear pleomorphism was present in 15/76 (20 %) of cases. This is not a ''new'' feature to MEC grading, however we illustrate it as it may be difficult to recognize. Nuclear pleomorphism in bone-fide MEC is characterized by coarse nuclear chromatin and single or multiple nucleoli. Importantly, nuclear atypia can be seen in the context of oncocytic metaplasia, which is not a manefestation of increased aggressive potential. Oncocytic atypia is characterized by increased nuclear size, prominent nucleoli, and coarse chromatin, and pink granular cytoplasm. Importantly, mitotic activity is not increased, and apoptosis or necrosis not seen in this context (Fig. 5) . Extreme nuclear pleomorphism is unusual in MEC, and if present, should raise the possibility of other diagnoses such as metastatic squamous carcinoma.
A major shortcoming of this study is that is retrospective and spans several decades. One-third of this cohort was diagnosed more than one decade ago, when electronic medical records (EMR) were not available in all of three institutions. The most significant information gaps were with respect to radiation therapy. We expected that a major proportion of patients should have received adjuvant radiotherapy based on resection margin status; this was not confirmed. The absence of any information in the medical records could not exclude the possibility that adjuvant radiotherapy was administered elsewhere. Therefore, multivariate analysis was not feasible in this study.
This study does confirm the ''down-grading trend'' of the AFIP grading system. Three patients with MEC classified as AFIP Grade 1 had positive cervical lymph nodes. Locoregional recurrence developed in two patients, and distant metastases occurred in one patient, with MEC classified as AFIP Grade 1. Unfortunately, this study was not powered to compare the predictive performance of the two grading schema due to the small number of patients who experienced disease progression and were reclassified with respect to grade (n = 3).
Luna [11] graded 43 parotid MEC by the AFIP criteria, the modified criteria, and the system that he and Batsakis [10] proposed; no attempt was made to correlate grade with outcome. Luna recommended our modified grading schema based on the combination of reproducibility, and lack of ''downgrading'' [11] . The Modified Grading schema can be further simplified by omitting the point values indicated in Table 1 . The presence of any single histological feature qualifies for classification as Grade 2 MEC; two or more histological features qualifies for classification as Grade 3 MEC. In the recent analysis by Nance and colleagues of 50 patients with MEC graded according to our modified criteria, no significant differences were seen in disease-free survival and overall survival between patients with lowand intermediate-grade MEC [12] . By contrast, the time intervals to the same outcomes were significantly different when comparing high-grade tumors with either intermediate-or low-grade MEC. 
